Professor Wei-Wei Zhang, MD PhD

How to Turning Science into 100x Returns: The Gene Therapy Blueprint from Lab to NYSE

Profile: A globally influential pioneer in gene therapy, successfully translating scientific discoveries into therapies and industries.
Scientific Contributions: Led development of “Gendicine,” the world’s first approved gene therapy for cancer (China NMPA, 2003).
Innovation: Invented MiniAdFVIII for hemophilia. Developed 2,600+ recombinant proteins, 800+ antibodies, holds 16 patents, and published 65+ papers.
Industry Builder: Founder/CEO of multiple biotech firms. Raised over $50M and co-founded a $300M VC/PE fund. Formerly led Baxter’s Gene Therapy Unit ($80M budget).
Translation: Created the “Three-Arrow” system (drugs, therapies, capital). Led GenStar to NYSE listing (100x value increase to $600M), providing treatments to 50,000+ patients globally.
boom

Outline:

The Dawn: Gendicine’s development journey, key challenges, and clinical impact.
Ecosystem: Strategic “Three-Arrow” approach: pioneering drugs, innovative therapies, and capital leverage.
Future: Gene therapy’s potential in oncology/rare diseases, current challenges/opportunities, and advice for innovators.

Role: Pioneer scientist-entrepreneur sharing end-to-end translation experience.

Discussion Points:

Collaboration Necessity: Multidisciplinary integration for breakthrough innovation.
Practical Challenges: Overcoming regulatory, technical, and commercial hurdles; managing global teams.
China’s Future: Enhancing global competitiveness and advice for biotech entrants.

Decode the Translation Puzzle – Hear him personally recount how he turned a research paper into the first gene therapy drug, avoiding the “valley of death” that 90% of scientists fall into.
Seize the Trillion-Dollar Track – Gain his precise predictions on gene therapy’s biggest breakthroughs in the next 3 years and get ahead in developing next-generation treatments.
Master the Capital Engine – Learn how he used the “Three-Arrow Strategy” to raise $300 million and drive his company’s valuation to a 100x growth.

The key decision-making framework for sciontists transitioning into antronronours
6 indicators to evaluate the commercial potential of any gene therapy project
Potential opportunities to connect with the global top-tier biotech investment community